Missing/wrong data?
Log in to edit
Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors.
scientific article published on 29 September 2017
Author/s
author: Marcin Skrzypski, Rafal Dziadziuszko, Amelia Szymanowska-Narloch
Work details
Publication date
September 29, 2017
-
-
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.